Clinical Trials Logo

Clinical Trial Summary

A 66-year-old man, with a history of uncontrolled type 2 diabetes, obesity with BMI 38, chronic kidney failure and chronic heart failure, was admitted to the Emergency Department with a large area of necrosis involving the perineal and perianal regions.


Clinical Trial Description

Fournier's gangrene is a potentially fatal emergency condition, supported by an infection of perineal and perianal region, characterized by necrotizing fasciitis with a rapid spread to fascial planes. FG, usually due to compromised host, may be sustained by many microbial pathogens. A 66-year-old man, with a history of uncontrolled type 2 diabetes, obesity with BMI 38, chronic kidney failure and chronic heart failure, was admitted to the Emergency Department with a large area of necrosis involving the perineal and perianal regions. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04694053
Study type Observational
Source University of Catania
Contact
Status Completed
Phase
Start date November 4, 2020
Completion date December 1, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT05116956 - SKin and Soft Tissue Necrotizing INfections in the Intensive Care Unit: a Prospective Multi-national Cohort Study
Completed NCT03443544 - Fournier's Gangrene and the Origin of the Infection as a Prognostic of Morbidity and Mortality, an Analysis of 121 Patients N/A
Completed NCT05529628 - The Immunological Differences Between Fournier Gangrene and Perianal Abscess
Completed NCT04983056 - Management of Fournier Gangrene at Ibn Rochd University Hospital Center
Completed NCT02180906 - Biomarkers in Patients With Flesh-eating Bacterial Infections N/A
Completed NCT03147352 - Prognosis and Treatment of Necrotizing Soft Tissue Infections: A Prospective Cohort Study
Completed NCT02501382 - Modulation of Biomarkers in Patients With Flesh-eating Bacterial Infections After With Hyperbaric Oxygen Treatment
Completed NCT02111161 - Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial Phase 2